Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ectoal
- Development stage
- Unknown
- Lead developer
- Alfa Intes
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Ectoal is a sterile, preservative-free ophthalmic solution developed by Alfa Intes. It contains 2% ectoin (ectoine), a natural extremolyte and cytoprotective amino acid derivative produced by halophilic bacteria. Ectoal is marketed as a CE Class I medical device indicated for the prevention and symptomatic treatment of allergic conjunctivitis. It works through a physical mechanism of action, where ectoin binds water molecules to form a stable, protective hydration shell (hydro-complex) over the ocular surface. This shield stabilizes cell membranes, reduces inflammation, and prevents allergens from contacting and penetrating the conjunctival epithelium, thereby relieving symptoms such as itching, redness, and excessive tearing.
- Brand names
- Ectoal
Beyond the preview
Go deeper on Ectoal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ectoal.